Terms: = Prostate cancer AND CDKN2A, CDK4I, 1029, ENSG00000147889, P42771, p14, CMM2, ARF, TP16, p16, MTS1, p19, p16INK4a, INK4a, CDKN2, p16INK4, p14ARF, MLM, INK4 AND Treatment
120 results:
1. Curcumin Enhances the Anti-cancer Efficacy of CDK4/6 Inhibitors in prostate cancer.
Zhao H; Ding R; Han J
Arch Esp Urol; 2024 Jan; 77(1):57-66. PubMed ID: 38374014
[TBL] [Abstract] [Full Text] [Related]
2. Female Bladder Dysfunction Following Boari Bladder Flap Ureteral Reconstruction.
Hardesty JK; Burns RT; Soyster ME; Jansen NE; Mellon M
Urology; 2024 Apr; 186():31-35. PubMed ID: 38369201
[TBL] [Abstract] [Full Text] [Related]
3. Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting.
Rautajoki KJ; Jaatinen S; Hartewig A; Tiihonen AM; Annala M; Salonen I; Valkonen M; Simola V; Vuorinen EM; Kivinen A; Rauhala MJ; Nurminen R; Maass KK; Lahtela SL; Jukkola A; Yli-Harja O; Helén P; Pajtler KW; Ruusuvuori P; Haapasalo J; Zhang W; Haapasalo H; Nykter M
Acta Neuropathol Commun; 2023 Nov; 11(1):176. PubMed ID: 37932833
[TBL] [Abstract] [Full Text] [Related]
4. Aridanin and oleanane-3- O-β-D-glucoside-2'-acetamide obtained from Tetrapleura tetraptera (Schumach. & Thonn) Taub. (Fabaceae) induces potent apoptotic activity in human prostate cancer cells.
Kamdem MHK; Zingue S; Grein T; Maxeiner S; Rutz J; Mmutlane EM; Njamen D; Blaheta RA; Ndinteh DT
J Ethnopharmacol; 2024 Jan; 319(Pt 3):117298. PubMed ID: 37866463
[TBL] [Abstract] [Full Text] [Related]
5. Senescent Tumor Cells Are Frequently Present at the Invasion Front: Implications for Improving Disease Control in Patients with Locally Advanced prostate cancer.
Schwarz S; Nientiedt C; Prigge ES; Kaczorowski A; Geisler C; Lucena Porcel C; von Knebel Doeberitz M; Hohenfellner M; Duensing S
Pathobiology; 2023; 90(5):312-321. PubMed ID: 37004506
[TBL] [Abstract] [Full Text] [Related]
6. Pan-cancer association of DNA repair deficiencies with whole-genome mutational patterns.
Sørensen SG; Shrikhande A; Poulsgaard GA; Christensen MH; Bertl J; Laursen BE; Hoffmann ER; Pedersen JS
Elife; 2023 Mar; 12():. PubMed ID: 36883553
[TBL] [Abstract] [Full Text] [Related]
7. Multi-candidate immunohistochemical markers to assess radiation response and prognosis in prostate cancer: results from the CHHiP trial of radiotherapy fractionation.
Wilkins A; Gusterson B; Tovey H; Griffin C; Stuttle C; Daley F; Corbishley CM; Dearnaley D; Hall E; Somaiah N
EBioMedicine; 2023 Feb; 88():104436. PubMed ID: 36708693
[TBL] [Abstract] [Full Text] [Related]
8. Diosgenin inhibits prostate cancer progression by inducing UHRF1 protein degradation.
Peng Y; Tang R; Ding L; Zheng R; Liu Y; Yin L; Fu Y; Deng T; Li X
Eur J Pharmacol; 2023 Mar; 942():175522. PubMed ID: 36681316
[TBL] [Abstract] [Full Text] [Related]
9. Assessing extra-prostatic extension for surgical guidance in prostate cancer: Comparing two PSMA-PET tracers with the standard-of-care.
Bahler CD; Green MA; Tann MA; Swensson JK; Collins K; Alexoff D; Kung H; Brocken E; Mathias CJ; Cheng L; Hutchins GD; Koch MO
Urol Oncol; 2023 Jan; 41(1):48.e1-48.e9. PubMed ID: 36333187
[TBL] [Abstract] [Full Text] [Related]
10. Synchronous Penile Squamous Cell Carcinoma, Bladder Urothelial Carcinoma and prostate Adenocarcinoma Diagnosed in One Procedure.
Deng F; Kong MX; Lai J
Anticancer Res; 2022 Jul; 42(7):3601-3605. PubMed ID: 35790255
[TBL] [Abstract] [Full Text] [Related]
11. treatment Represents a Key Driver of Metastatic cancer Evolution.
Christensen DS; Ahrenfeldt J; Sokač M; Kisistók J; Thomsen MK; Maretty L; McGranahan N; Birkbak NJ
Cancer Res; 2022 Aug; 82(16):2918-2927. PubMed ID: 35731928
[TBL] [Abstract] [Full Text] [Related]
12. Clinical Significance of Gene Mutations and Polymorphic Variants and their Association with prostate cancer Risk in Polish Men.
Heise M; Jarzemski P; Nowak D; Bąk A; Junkiert-Czarnecka A; Pilarska-Deltow M; Borysiak M; Pilarska B; Haus O
Cancer Control; 2022; 29():10732748211062342. PubMed ID: 35638715
[No Abstract] [Full Text] [Related]
13. UBE2S as a novel ubiquitinated regulator of p16 and β-catenin to promote bone metastasis of prostate cancer.
Peng S; Chen X; Huang C; Yang C; Situ M; Zhou Q; Ling Y; Huang H; Huang M; Zhang Y; Cheng L; Zhang Q; Guo Z; Lai Y; Huang J
Int J Biol Sci; 2022; 18(8):3528-3543. PubMed ID: 35637955
[TBL] [Abstract] [Full Text] [Related]
14. KMT2C methyltransferase domain regulated ink4a expression suppresses prostate cancer metastasis.
Limberger T; Schlederer M; Trachtová K; Garces de Los Fayos Alonso I; Yang J; Högler S; Sternberg C; Bystry V; Oppelt J; Tichý B; Schmeidl M; Kodajova P; Jäger A; Neubauer HA; Oberhuber M; Schmalzbauer BS; Pospisilova S; Dolznig H; Wadsak W; Culig Z; Turner SD; Egger G; Lagger S; Kenner L
Mol Cancer; 2022 Mar; 21(1):89. PubMed ID: 35354467
[TBL] [Abstract] [Full Text] [Related]
15. Dihydroartemisinin induces cell apoptosis through repression of UHRF1 in prostate cancer cells.
Xia T; Liu S; Xu G; Zhou S; Luo Z
Anticancer Drugs; 2022 Jan; 33(1):e113-e124. PubMed ID: 34387595
[TBL] [Abstract] [Full Text] [Related]
16. Computerized tumor multinucleation index (MuNI) is prognostic in p16+ oropharyngeal carcinoma.
Koyuncu CF; Lu C; Bera K; Zhang Z; Xu J; Toro P; Corredor G; Chute D; Fu P; Thorstad WL; Faraji F; Bishop JA; Mehrad M; Castro PD; Sikora AG; Thompson LD; Chernock RD; Lang Kuhs KA; Luo J; Sandulache V; Adelstein DJ; Koyfman S; Lewis JS; Madabhushi A
J Clin Invest; 2021 Apr; 131(8):. PubMed ID: 33651718
[TBL] [Abstract] [Full Text] [Related]
17. Acquired radioresistance in cancer associated fibroblasts is concomitant with enhanced antioxidant potential and DNA repair capacity.
Domogauer JD; de Toledo SM; Howell RW; Azzam EI
Cell Commun Signal; 2021 Feb; 19(1):30. PubMed ID: 33637118
[TBL] [Abstract] [Full Text] [Related]
18. Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability.
Shrestha R; Llaurado Fernandez M; Dawson A; Hoenisch J; Volik S; Lin YY; Anderson S; Kim H; Haegert AM; Colborne S; Wong NKY; McConeghy B; Bell RH; Brahmbhatt S; Lee CH; DiMattia GE; Le Bihan S; Morin GB; Collins CC; Carey MS
Cancer Res; 2021 Apr; 81(7):1681-1694. PubMed ID: 33441310
[TBL] [Abstract] [Full Text] [Related]
19. Sulforaphane Reduces prostate cancer Cell Growth and Proliferation In Vitro by Modulating the Cdk-Cyclin Axis and Expression of the CD44 Variants 4, 5, and 7.
Rutz J; Thaler S; Maxeiner S; Chun FK; Blaheta RA
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33218199
[TBL] [Abstract] [Full Text] [Related]
20. Synthetic Lethal Metabolic Targeting of Androgen-Deprived prostate cancer Cells with Metformin.
Yang B; Damodaran S; Khemees TA; Filon MJ; Schultz A; Gawdzik J; Etheridge T; Malin D; Richards KA; Cryns VL; Jarrard DF
Mol Cancer Ther; 2020 Nov; 19(11):2278-2287. PubMed ID: 32943543
[TBL] [Abstract] [Full Text] [Related]
[Next]
